By investing in research that considers structural factors—such as socioeconomic status, neighborhood environment, and systemic inequality—NIDA can support the development of more effective, equitable treatment programs. The National Institute on Drug Abuse (NIDA) stands at the forefront of drug rehabilitation research and innovation. For over five decades, NIDA has been instrumental in expanding our understanding of addiction, developing effective treatment tools, and informing public policies that influence recovery practices nationwide.
Looking for Treatment?
Ecstasy sold on the street is seldom pure MDMA and often gets mixed with other drugs like cocaine, ketamine, and amphetamines. Ecstasy is often abused due to the highly euphoric and happy effects of the drug on the brain by increasing serotonin, norepinephrine, and dopamine levels. NIH did not address our recommendations to correct the improper funding for the first 3 program years of the Contract. Until NIH makes these adjustments, HHS cannot report the correct amount of its Antideficiency Act violation.
Suggestions to Help You Through Being Faced with Drugs in Recovery
Policy initiatives supporting funding and infrastructure are essential to scaling these approaches, ultimately contributing to more comprehensive and equitable SUD treatment landscapes. The NIH Stage Model serves as a roadmap for developing, testing, and implementing interventions for SUDs. It outlines sequential phases, starting from basic research acting as proof of concept (Stage I), progressing through treatment refinement (Stage II), effectiveness testing (Stage III), and finally dissemination and implementation (Stages IV and V).
Monitoring the Future Survey: Why we Study Teen Drug Use, a Message to Parents
Combining digital interventions with pharmacotherapy and counseling can produce comprehensive, cost-effective, and sustainable recovery programs. Beyond research, NIDA plays a critical role in shaping policies related to drug treatment and prevention. Its scientific findings inform legislation supporting medication approvals and public health campaigns. This information guides policymakers, healthcare providers, and researchers in designing targeted interventions and allocating resources efficiently.
- After four weeks of incubation, a 30% loss in LSD concentration at 37 °C and up to a 40% at 45 °C were observed.
- The initial contract action obligated funds only for program year 1 (July 9, 2007, through July 8, 2008).
- The National Institute on Drug Abuse (NIDA) is a vital part of the federal government under the National Institutes of Health (NIH).
- The National Institute on Drug Abuse (NIDA) actively promotes the development of incentive-based treatments for substance use disorders (SUDs).
Development and approval of medications for substance use disorders
As part of its mission, it has begun emphasizing research into social determinants of health and normative drug use to reduce stigmas and improve treatment access for marginalized populations. In addition, NIDA’s studies explore genetic, environmental, and societal factors that influence drug use. These insights have led to the development of personalized interventions tailored to individual needs, improving treatment efficacy. NIDA-supported research leads to FDA approval of nalmefene nasal spray(link is external), which can be used to treat fentanyl overdose. 2023 — A study under the NIH Heal Initiative shows that initiating buprenorphine treatment in the ER is safe, effective and does not trigger withdrawal in people with opioid use disorder. 2012 — A NIDA-supported seminal study demonstrates that scaling up HIV treatment in people who inject drugs results in reductions in community-level viral load and HIV transmission.
MDMA first became popular in nightclubs, but people now take it in a wide range of settings. Researchers are also studying MDMA as a treatment for depression and post-traumatic stress disorder (PTSD) in supervised clinical research trials. Brain imaging studies of people with addiction show physical changes in areas of the brain that are critical to judgment, decision-making, learning and memory, and behavior control.12 These changes help explain the compulsive nature of addiction. But with continued use, a person’s ability to exert self-control can become seriously impaired. Another related complication of fentanyl overdoses includes the so-called wooden chest syndrome, which quickly induces complete respiratory failure by paralyzing the thoracic muscles, explained in more detail in the Muscle rigidity section below.
- Its discovery, along with other parts of the natural opioid system in the brain, revolutionizes the addiction field.
- 2000 — Researchers demonstrate that contingency management for cocaine use disorder can have long-lasting effects and serve as a valuable role in treating addictions.
- Information about working at the National Institute of Drug Abuse, including open positions.
- Copyright © 2025, AddictionHelp.com The information provided by AddictionHelp.com is not a substitute for professional medical advice.
- Overall, incentive-based treatments represent a promising frontier in individualized care for substance use disorders.
Monitoring the Future Study and Population Assessment of Tobacco and Health (PATH) study data show that flavored e-cigarette products particularly appeal to youth. Food and Drug Administration (FDA) policy prioritizing enforcement against certain unauthorized flavored cartridge-based products. Using this method, researchers are able to show that opioid receptors function in different cell locations what is mdma national institute on drug abuse nida depending on the type of opioid. NIDA-supported research leads to the FDA approval of lofexidine, the first non-opioid treatment for opioid withdrawal. 2014 — NIDA announces the development of an innovative National Drug Early Warning System (NDEWS) to monitor emerging nationwide new and emerging drug trends to help public health experts respond quickly.
What is NIDA’s support for incentive-based treatments for SUDs?
NIDA-supported research demonstrates that methadone is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a comprehensive methadone treatment program. 1998 — As part of a team including the Pasteur Institute, Karolinska Institute and Glaxo Wellcome Geneva, a NIDA-supported researcher identifies a brain receptor activated by nicotine use. In recent years, NIDA has taken steps to address these disparities through the Racial Equity Initiative (REI). This program was established after 2020, with aims to reduce racial disparities in drug use research and treatment outcomes. It emphasizes increasing funding for Black primary investigators, studying social determinants of health, and understanding normative drug use behaviors across different populations. Researchers are encouraged to explore opportunities aligned with the NIH’s strategic priorities, such as the development of innovative digital health tools or behavioral interventions.
Consider how a social drinker can become intoxicated, get behind the wheel of a car, and quickly turn a pleasurable activity into a tragedy that affects many lives. Occasional drug use, such as misusing an opioid to get high, can have similarly disastrous effects, including impaired driving and overdose. Our mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health.
2022 — The Mainstreaming Addiction Treatment (MAT) Act and The Medication Access and Training Expansion (MATE) Act of the Consolidated Appropriations Act, 2023, were signed into law on December 29, 2022. 2022 — The Mainstreaming Addiction Treatment (MAT) Act and The Medication Access and Training Expansion (MATE) Act of the Consolidated Appropriations Act, 2023, were signed into law on December 29, 2022. One of NIDA’s significant contributions lies in its support for developing medications that treat various substance use disorders. The institute’s research has led to the creation and FDA approval of vital medications such as buprenorphine, naloxone nasal spray, and lofexidine. These drugs address different needs in addiction treatment, from reducing withdrawal symptoms to preventing overdose.